{"title": "E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy - Full Text View - ClinicalTrials.gov", "author": null, "url": "https://clinicaltrials.gov/ct2/show/NCT02879006", "hostname": "clinicaltrials.gov", "description": "E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy - Full Text View.", "sitename": "ClinicalTrials.gov", "date": "2016-08-25", "cleaned_text": "(Omalizumab) for Food Allergy | The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our | |ClinicalTrials.gov Identifier: NCT02879006| | | Recruitment Status : Unknown Verified August 2020 by Xiu-Min Li, Icahn School of Medicine at Mount Sinai. Recruitment status was: Active, not recruiting First Posted : August 25, 2016 Last Update Posted : August 12, 2020 - Study Details [Tabular View](/ct2/show/record/NCT02879006) [No Results Posted](/ct2/show/results/NCT02879006) |Official Title:||Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of Chinese Herbal Therapy and Multiple Food Allergen Oral Immunotherapy| |Study Start Chinese Herbal Medication | Capsules, 26 month course, starting 2 months pre-OIT Other Name: E-B-FAHF-2 Drug: Omalizumab 4 months course, starting 2 months pre-OIT through the 2 month build-up phase Other Name: Xolair\u00ae Drug: Multi OIT 24 months of multi OIT (maintenance dose of 1gm each food allergen) |Placebo Comparator: Placebo|| Drug: Placebo | Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT Other Name: Placebo Chinese Herb Drug: Omalizumab 4 months course, starting 2 months pre-OIT through the 2 month build-up phase Other Name: Xolair\u00ae Drug: Multi OIT 24 months of multi OIT (maintenance dose of 1gm each food allergen) - Sustained unresponsiveness [ Time Frame: month 29 ]Sustained unresponsiveness evaluated by the absence of dose-limiting symptoms to a cumulative dose of 4,444 protein. - Desensitizing to 4444mg [ Time Frame: month 26 ]Number of participants tolerating a cumulative dose of 4,444mg of food allergen protein. - High level of desensitization to 7444mg or higher [ Time Frame: month 26 ]Number of participants tolerating a cumulative dose of 7,444mg or higher (max of 10,444mg) of food allergen protein Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies.](/ct2/about-studies/learn) |Ages Eligible for Study:||6 Years to 40 Years (Child, |Sexes Eligible for Study:||All| |Accepts Healthy Volunteers:||No| Inclusion Criteria: - 6 through 40 years - At least one of the following for each of the 3 study allergens: serum IgE >4 kU/L or skin prick test >6mm - dose limiting symptoms at a cumulative dose of <=444 mg protein for 3 allergens as screening double-blind, placebo-controlled food challenge - use of an effective method of contraception by females of child-bearing potential - ability to ingest oat or corn with no allergic reaction Exclusion Criteria: - If baked milk or egg are tolerated (assessed by clinical report), then milk or egg may not be included as a study allergen - Any disorder in which epinephrine is contraindicated such as coronary artery disease, uncontrolled hypertension, and serious ventricular arrhythmias - History of other chronic disease requiring therapy (other than asthma, atopic dermatitis, or rhinitis) - History of eosinophilic gastrointestinal disease - Current participation in any other interventional study - Investigational drug use within 90 days - Subject is on build-up phase of any allergen immunotherapy (prior to maintenance dosing) - Current uncontrolled moderate to severe asthma as defined by: - FEV1 value <80% predicted (or PFR if unable to perform spirometry) or any clinical features of moderate or severe persistent asthma baseline severity (as defined by the 2007 NHLBI Guidelines) and greater than high daily doses of inhaled corticosteroids (as defined for children and adults using dosing tables from the 2007 NHLBI Guidelines). - Use of steroid medications in the following manners: history of daily oral steroid dosing for >1 month during the past year, having 1 burst or steroid course within the past 6 months, or having >1 burst oral steroid course within the past 12 months. - Asthma requiring >1 hospitalization in the past year for asthma or >1 ED visit in the past 6 months for asthma. - Use of systemic steroid medications (IV, IM or oral) for indications other than asthma for > 3 weeks within the past 6 months - Inability to discontinue antihistamines for the initial day of escalation, skin testing or DBPCFC - Use of Xolair\u00ae (omalizumab) within the past 6 months - Known sensitivity to Xolair\u00ae (omalizumab) or to the class of study drugs - Body weight more than 90 kg, or subjects with weight-IgE combination that yields a dose requirement greater than 600 mg dosing - Use of beta-blockers (oral), (ACE) inhibitors, angiotensin-receptor blockers or calcium channel blockers - Pregnancy or lactation - Inability to swallow placebo capsules - Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier |United York| |Icahn School of Medicine at Mount Sinai| |New York, New York, United States, 10029| |Principal Investigator:||Julie MD||Icahn School of Medicine at Mount Sinai| |Responsible Party:||Xiu-Min Li, Professorial Lecturer, Icahn School Mount Sinai| |ClinicalTrials.gov Identifier:|| |[Key Record Dates](/ct2/keydates/NCT02879006) | Chinese herbal therapy | Oral immunotherapy Food allergy Omalizumab | Hypersensitivity | Food Hypersensitivity Immune System Diseases Hypersensitivity, Immediate | Omalizumab | Anti-Allergic Agents Anti-Asthmatic Agents Respiratory System Agents "}